New Indication: Osimertinib as adjuvant therapy for EGFR-mutated NSCLC
|New Indication: Osimertinib as adjuvant therapy for EGFR-mutated NSCLC|
Double-blind, phase 3 trial (ADAURA)
N Engl J Med 2020; 383:1711-1723
Reviewed by Ulas Darda Bayraktar, MD on Dec 22, 2020
Altai Chemo Planner
Quickly Prepare Accurate Chemotherapy Orders
Altai Chemo Planner employs Altai Protocol Library that includes over 1000 chemotherapy protocols for both Hematology and Oncology. You can find major guidelines' protocols, parenteral, and oral, in the library. Altai Protocol Library is frequently and regularly updated.